ProteinLogic Appoints Dr Adrian Woolfson as Non-Executive Director

CAMBRIDGE, UK (2019-06-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Adrian Woolfson as Non-Executive Director.

Dr Woolfson is the founder of ProteinLogic, having discovered soluble Cluster of Differentiation antigens that underpin ProteinLogic’s platform technology.

He is currently serving as Executive Vice President of Research & Development, Sangamo Inc., CA, USA. Dr. Woolfson has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Previously, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the development of the company’s off-the-shelf and personalized neoantigen vaccine and oncolytic virus strategy. Prior to Nouscom, Dr. Woolfson served as Global Clinical Leader, Early and Late Stage Immuno-Oncology/Hematology at Pfizer Inc. in New York, and was responsible for defining Pfizer’s hematology immuno-oncology strategy and building its immuno-oncology hematological malignancies portfolio. Prior to that he was the Global Lead for Pfizer’s SMO inhibitor glasdegib, which received FDA approval in 2018. From 2007 to 2013, Dr. Woolfson held roles of increasing responsibility at Bristol-Myers Squibb, including Global Medical Lead for a first-in-human CDC7 inhibitor and selective JAK2 inhibitor.

Dr. Woolfson completed his post-graduate training in internal medicine at Addenbrooke’s Hospital, Cambridge, UK. He holds a BM BCh degree in Clinical Medicine from Oxford University and completed his PhD in molecular immunology at Cambridge University. He was the Charles and Katherine Darwin Research Fellow at Darwin College Cambridge, and a Wellcome Trust Clinical Research Fellow. He completed his doctoral and post-doctoral work in the laboratory of Nobel Prize winner and inventor of monoclonal antibodies Dr César Milstein in the Division of Protein and Nucleic Acid Chemistry at the MRC Laboratory of Molecular Biology in Cambridge, UK.

Dr Nicolas Huber, CEO of ProteinLogic, said: “We are delighted to have Dr Woolfson, the founder of ProteinLogic, back on the company board. He is joining at a turning point for the company as we have entered a commercial phase with our first clinically validated asset for the diagnosis of Tuberculosis. His extensive expertise in the field will be crucial to guiding ProteinLogic through its first commercial endeavours. His vision will ensure that the long-term direction of the company is on a firm footing for growth, beyond Tuberculosis into other indications of significant medical need. We are excited to welcome him back on board”.